<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730298</url>
  </required_header>
  <id_info>
    <org_study_id>NICSO-GINSENG</org_study_id>
    <nct_id>NCT03730298</nct_id>
  </id_info>
  <brief_title>American Ginseng for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients</brief_title>
  <official_title>American Ginseng (Panax Quinquefolius) for the Prevention of Moderate-severe Fatigue in Breast Cancer Patients Submitted to Adjuvant Chemotherapy After Surgery. A Study of NICSO (Network Italiano Cure di Supporto in Oncologia).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Network Italiano Cure di Supporto in Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera di Perugia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Associazione Umbra per la lotta Contro il Cancro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Avanti Tutta Onlus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Network Italiano Cure di Supporto in Oncologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among the symptoms referred by cancer patients, cancer related fatigue (CRF) is one of the
      most disabling symptom with a relevant impact on the quality of life.

      CRF can occur before, during and after anti-cancer treatment. The aim of the present study is
      to verify the efficacy of American Ginseng in preventing or reducing the intensity of
      moderate-severe CRF in breast cancer women receiving adjuvant chemotherapy with
      anthracyclines plus cyclophosphamide after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer related fatigue (CRF) can occur before, during and after anti-cancer treatment. In
      fact, up to 40% of patients report fatigue at diagnosis, 80%-90% during chemotherapy and
      radiotherapy, respectively and 20%-50% in the post-treatment phase.

      All cancer patients should be screened for the presence of CRF at the first oncological visit
      and subsequently during and after the anticancer therapies.

      If the patient refers CRF, it could be quantified with one of the validate instruments
      available; the possible determinants could be identified and corrected if possible, to reduce
      their impact on patients CR.

      The most evaluated pharmacological treatments of CRF include psychostimulants
      (methylphenidate, modafinil, armodafinil) and dexamethasone. Non-pharmacological treatments
      include physical exercise, psychological therapies and complementary therapies such as
      agopuncture, yoga, ginseng.

      The aim of the present study is to verify the efficacy of American Ginseng in preventing or
      reducing the intensity of moderate-severe CRF in a homogeneous population of breast cancer
      women submitted to adjuvant chemotherapy with anthracyclines plus cyclophosphamide after
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cancer related fatigue during chemotherapy.</measure>
    <time_frame>The NRS will be admistered before randomization (baseline assessment) and before each chemotherapy cycle. In addition, the patients must complete the NRS once a day at home, for 90 days.</time_frame>
    <description>Incidence will be evaluated through the Numeric Rating Scale (NRS). NRS is a linear numeric scale, from 0 = no fatigue to 10 = the worst possible fatigue. A NRS value ≥ 4 indicates the presence of a signficative fatigue (moderate-severe fatigue).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of cancer related fatigue during chemotherapy.</measure>
    <time_frame>The NRS will be admistered before randomization (baseline assessment) and before each chemotherapy cycle. In addition, the patients must complete the NRS once a day at home, for 90 days.</time_frame>
    <description>Intensity will be evaluated through the Numeric Rating Scale (NRS). NRS is a linear numeric scale, from 0 = no fatigue to 10 = the worst possible fatigue. A NRS value ≥ 4 indicates the presence of a signficative fatigue (moderate-severe fatigue).moderate-severe fatigue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>These questionnaires will be administered at baseline (before randomization) and immediately before each chemotherapy cycle.</time_frame>
    <description>QoL will be evaluated through validated instruments: the Brief Fatigue Inventory (BFI) and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30), Italian version.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Cancer Related Fatigue</condition>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>American Ginseng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 1 cpr twice a day orally for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>American Ginseng</intervention_name>
    <description>cpr</description>
    <arm_group_label>American Ginseng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>cpr</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  submitted for the first time to adjuvant chemotherapy with anthracyclines and
             cyclophosphamide after surgery for breast cancer;

          -  not presenting CRF or at least with o al massimo CRF lieve (NRS &lt; 4);

          -  18 year old, who have given written informermed consent;

          -  who accept to use adequate contraceptive methods, if they are of child-bearing
             potential.

        Exclusion Criteria:

          -  previously submitted to chemotherapy;

          -  with concomitant not-correctable alterations, present before chemotherapy, possible
             determinants of fatigue (NRS ≥ 4), such as anemia, not well controlled pain, insomnia,
             electrolyte imbalance, dehydration, anorexia/cachexia, hepatic, renal or heart
             failure, adrenocortical failure, neurological deficit, hypothyroidism, not-controlled
             diabetes mellitus;

          -  submitted to raitherapy during the 15 days before the randomization;

          -  presenting moderate-severe fatigue (NRS ≥ 4) at basaline;

          -  receivind opioids or corticosteroids (except if admimistered at phisiological doses or
             to prevent emesis on the chemotherapy day);

          -  with with blood cell count &lt; 3000/mm3, platelets &lt; 70000 mm3, hemoglobin &lt; 8 g/dL;

          -  unable to understand the procedures of the study or to collaborate with them;

          -  pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncology Department, Perugia Hospital</name>
      <address>
        <city>Perugia</city>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto Roila, Dr</last_name>
      <phone>+39(0)755784099</phone>
      <email>roila.fausto@libero.it</email>
    </contact>
    <contact_backup>
      <last_name>Sonia Fatigoni, Dr</last_name>
      <phone>+39(0)755784099</phone>
      <email>fatisoni@libero.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Koornstra RH, Peters M, Donofrio S, van den Borne B, de Jong FA. Management of fatigue in patients with cancer -- a practical overview. Cancer Treat Rev. 2014 Jul;40(6):791-9. doi: 10.1016/j.ctrv.2014.01.004. Epub 2014 Feb 7. Review.</citation>
    <PMID>24576643</PMID>
  </results_reference>
  <results_reference>
    <citation>Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, Duane S, Mattar B, Liu H, Atherton PJ, Christensen B, Loprinzi CL. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010 Feb;18(2):179-87. doi: 10.1007/s00520-009-0642-2. Epub 2009 May 6.</citation>
    <PMID>19415341</PMID>
  </results_reference>
  <results_reference>
    <citation>Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013 Aug 21;105(16):1230-8. doi: 10.1093/jnci/djt181. Epub 2013 Jul 13.</citation>
    <PMID>23853057</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Network Italiano Cure di Supporto in Oncologia</investigator_affiliation>
    <investigator_full_name>Fausto Roila</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>American Ginseng</keyword>
  <keyword>Cancer related fatigue</keyword>
  <keyword>Breast Cancer Female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

